Related Experiment Video
Updated: Apr 17, 2026
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Combination and triple therapy in patients with stable angina pectoris not adequately controlled by optimal β-blocker
Insights
Beta-blocker monotherapy effectively treats stable angina pectoris. For patients not responding, adding a calcium antagonist offers greater benefit than nitrates, though overall benefits of combination therapy are limited.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable angina pectoris (SAP) is often treated with beta-blocker monotherapy, effective in 60-80% of low-risk patients.
- Limited evidence exists on the benefits of combination or triple therapy for SAP patients inadequately responding to beta-blockers.
Approach:
- A literature review was conducted to assess the effectiveness of combination and triple therapy in managing stable angina pectoris.
- Evidence from existing studies was synthesized to evaluate treatment strategies beyond beta-blocker monotherapy.
Key Points:
- Combination therapy (beta-blocker with calcium antagonist or nitrate) is more effective than beta-blocker monotherapy, but objective benefits are seen in only ~30% of patients.
- Beta-blocker plus calcium antagonist therapy is superior to beta-blocker plus nitrate therapy.
- Adding a calcium antagonist to beta-blocker monotherapy is more effective than switching to a calcium antagonist alone.
Conclusions:
- Combination therapy offers incremental benefits for some stable angina patients, with calcium antagonists showing particular efficacy.
- Triple therapy is generally not recommended for mild angina but may benefit severe cases unresponsive to combination therapy, though data is limited.
Abstract:
In 60 to 80% of patients with stable angina pectoris at low risk for future coronary events, monotherapy with a β-blocker is an effective treatment. When patients with stable angina pectoris and low risk for events do not respond adequately to optimal β-blocker monotherapy, combination therapy or even triple therapy is may be recommended, but little is known of the actual benefit of such a strategy. We reviewed the evidence from the literature on the effectiveness of combination and triple therapy. Combination therapy with a calcium antagonist or nitrate was found to be more effective than β-blocker monotherapy in the majority of studies, but only an estimated 30% of patients objectively benefit from these combination therapies. Direct comparison shows that combination therapy of a β-blocker with a calcium antagonist is more effective than the combination of a β-blocker with a nitrate. An inadequate response to β-blocker monotherapy is more effectively improved by addition of a calcium antagonist than by alternative use of a calcium antagonist. The use of triple therapy is controversial and not recommended in patients with mild angina pectoris, while for patients with severe angina pectoris not responding to combination therapy of a β-blocker with a nitrate, triple therapy may be of advantage, although the number of patients studied has been small.
Related Concept Videos
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....